Hokkaido University researchers have uncovered a cellular protein that stabilizes a tumor promoting signaling pathway, suggesting a new target to treat prostate cancer. The drug Gefitinib is used to treat breast, lung, and other cancers by inhibiting epidermal growth factor receptor (EGFR) signaling, but it has only a limited effect on prostate cancer. EGFR, present on the cell membrane, is involved in cell proliferation and the development of dermis, lung, and digestive tissues. When a mutation causes its over-activation, it can lead to increased cell proliferation and tumor formation.
See original article at: https://www.sciencedaily.com/releases/2017/12/171222093209.htm
Post a comment